AbbVie (ABBV) Financials

$180.53 +3.48 (+1.97%)

As of 03:59 PM Eastern

Annual Income Statements for AbbVie

This table shows AbbVie's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	5,144	5,953	5,309	5,687	7,882	4,616	11,542	11,836	4,863	4,278
Consolidated Net Income / (Loss)	5,144	5,953	5,309	5,687	7,882	4,622	11,549	11,845	4,873	4,286
Net Income / (Loss) Continuing Operations	5,144	5,953	5,309	5,687	7,882	4,622	11,549	11,845	4,873	4,286
Total Pre-Tax Income	6,645	7,884	7,727	5,197	8,426	3,398	12,989	13,477	6,250	3,716
Total Operating Income	7,537	9,340	9,545	6,383	12,983	11,363	17,924	18,117	12,757	9,137
Total Gross Profit	18,359	19,806	21,174	25,035	25,827	29,041	38,751	39,943	33,125	39,430
Total Revenue	22,859	25,638	28,216	32,753	33,266	45,804	56,197	58,054	54,318	56,334
Operating Revenue	22,859	25,638	28,216	32,753	33,266	45,804	56,197	58,054	54,318	56,334
Total Cost of Revenue	4,500	5,832	7,042	7,718	7,439	16,763	17,446	18,111	21,193	16,904
Operating Cost of Revenue	4,500	5,832	7,042	7,718	7,439	16,763	17,446	18,111	21,193	16,904
Total Operating Expenses	10,822	10,466	11,629	18,652	12,844	17,678	20,827	21,826	20,368	30,293
Selling, General & Admin Expense	6,387	5,881	6,295	7,399	6,942	11,299	13,473	15,260	12,872	17,509
Research & Development Expense	4,435	4,585	5,334	10,753	6,792	6,379	6,922	6,510	7,675	12,791
Other Operating Expenses / (Income)	-	-	0.00	500	-890	0.00	432	56	-179	-7.00
Total Other Income / (Expense), net	-892	-1,456	-1,818	-1,186	-4,557	-7,965	-4,935	-4,640	-6,507	-5,421
Interest & Investment Income	-686	-965	-1,004	-1,144	-1,509	-2,280	-2,384	-2,044	-1,684	-2,160
Other Income / (Expense), net	-206	-491	-814	-42	-3,048	-5,685	-2,551	-2,596	-4,823	-3,261
Income Tax Expense	1,501	1,931	2,418	-490	544	-1,224	1,440	1,632	1,377	-570
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	-	0.00	0.00	6.00	7.00	9.00	10	8.00
Basic Earnings per Share	$3.15	$3.65	$3.31	$3.67	$5.30	$2.73	$6.48	$6.65	$2.73	$2.40
Weighted Average Basic Shares Outstanding	1.63B	1.62B	1.60B	1.54B	1.48B	1.67B	1.77B	1.77B	1.77B	1.77B
Diluted Earnings per Share	$3.13	$3.63	$3.30	$3.66	$5.28	$2.72	$6.45	$6.63	$2.72	$2.39
Weighted Average Diluted Shares Outstanding	1.64B	1.63B	1.60B	1.55B	1.48B	1.67B	1.78B	1.78B	1.77B	1.77B
Weighted Average Basic & Diluted Shares Outstanding	1.63B	1.63B	1.60B	1.55B	1.48B	1.77B	1.77B	1.77B	1.77B	1.77B

This table shows AbbVie's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	924	3,949	2,473	239	2,024	1,778	822	1,369	1,370	1,561	-22
Consolidated Net Income / (Loss)	928	3,952	2,472	241	2,027	1,781	824	1,372	1,373	1,564	-23
Net Income / (Loss) Continuing Operations	928	3,952	2,472	241	2,027	1,781	824	1,372	1,373	1,564	-23
Total Pre-Tax Income	1,183	4,400	2,965	475	2,610	1,953	1,212	1,755	2,146	2,084	-2,269
Total Operating Income	3,295	4,603	5,502	2,768	4,513	2,281	3,195	2,798	3,998	3,831	-1,490
Total Gross Profit	10,144	9,750	10,708	8,089	9,625	7,376	8,035	8,052	9,323	10,248	11,807
Total Revenue	14,583	14,812	15,121	12,225	13,865	13,927	14,301	12,310	14,462	14,460	15,102
Operating Revenue	14,583	14,812	15,121	12,225	13,865	13,927	14,301	12,310	14,462	14,460	15,102
Total Cost of Revenue	4,439	5,062	4,413	4,136	4,240	6,551	6,266	4,258	5,139	4,212	3,295
Operating Cost of Revenue	4,439	5,062	4,413	4,136	4,240	6,551	6,266	4,258	5,139	4,212	3,295
Total Operating Expenses	6,849	5,147	5,206	5,321	5,112	5,095	4,840	5,254	5,325	6,417	13,297
Selling, General & Admin Expense	5,412	3,304	3,417	3,039	3,548	3,372	2,913	3,315	3,377	4,287	6,530
Research & Development Expense	1,609	1,614	1,790	2,292	1,733	1,723	1,927	1,939	1,948	2,130	6,774
Other Operating Expenses / (Income)	-172	229	-1.00	-10	-169	0.00	-	0.00	0.00	0.00	-7.00
Total Other Income / (Expense), net	-2,112	-203	-2,537	-2,293	-1,903	-328	-1,983	-1,043	-1,852	-1,747	-779
Interest & Investment Income	-532	-497	-476	-454	-454	-398	-378	-453	-506	-591	-610
Other Income / (Expense), net	-1,580	294	-2,061	-1,839	-1,449	70	-1,605	-590	-1,346	-1,156	-169
Income Tax Expense	255	448	493	234	583	172	388	383	773	520	-2,246
Net Income / (Loss) Attributable to Noncontrolling Interest	4.00	3.00	-1.00	2.00	3.00	3.00	2.00	3.00	3.00	3.00	-1.00
Basic Earnings per Share	$0.52	$2.22	$1.39	$0.13	$1.14	$1.00	$0.46	$0.77	$0.77	$0.88	($0.02)
Weighted Average Basic Shares Outstanding	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B
Diluted Earnings per Share	$0.51	$2.21	$1.40	$0.13	$1.14	$1.00	$0.45	$0.77	$0.77	$0.88	($0.03)
Weighted Average Diluted Shares Outstanding	1.78B	1.78B	1.78B	1.78B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B
Weighted Average Basic & Diluted Shares Outstanding	1.77B	1.77B	1.77B	1.76B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B

This table details how cash moves in and out of AbbVie's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	51	-3,299	4,203	-2,014	32,635	-31,475	1,297	-545	3,613	-7,290
Net Cash From Operating Activities	7,535	7,041	9,960	13,427	13,324	17,588	22,777	24,943	22,839	18,806
Net Cash From Continuing Operating Activities	7,535	7,041	9,960	13,427	13,324	17,588	22,777	24,943	22,839	18,806
Net Income / (Loss) Continuing Operations	5,144	5,953	5,309	5,687	7,882	4,622	11,549	11,845	4,873	4,286
Consolidated Net Income / (Loss)	5,144	5,953	5,309	5,687	7,882	4,622	11,549	11,845	4,873	4,286
Depreciation Expense	417	425	425	471	464	666	803	778	752	764
Amortization Expense	419	764	1,076	1,294	1,553	5,805	7,718	7,689	7,946	7,622
Non-Cash Adjustments To Reconcile Net Income	1,051	1,360	2,515	7,052	1,663	2,961	2,157	3,895	4,216	6,594
Changes in Operating Assets and Liabilities, net	504	-1,461	635	-1,077	1,762	3,534	550	736	5,052	-460
Net Cash From Investing Activities	-12,936	-6,074	-274	-1,006	596	-37,557	-2,344	-623	-2,009	-20,820
Net Cash From Continuing Investing Activities	-12,936	-6,074	-274	-1,006	596	-37,557	-2,344	-623	-2,009	-20,820
Purchase of Property, Plant & Equipment	-532	-479	-529	-638	-552	-798	-787	-695	-777	-974
Acquisitions	-11,488	-2,495	-	0.00	0.00	-38,260	-525	-255	0.00	-17,493
Purchase of Investments	-1,815	-5,577	-2,538	-2,528	-1,718	-1,411	-1,496	-1,977	-1,300	-3,097
Sale and/or Maturity of Investments	899	2,359	2,793	2,160	2,699	1,525	98	1,530	55	555
Other Investing Activities, net	0.00	118	0.00	0.00	167	1,387	366	774	13	189
Net Cash From Financing Activities	5,771	-3,928	-5,512	-14,396	18,708	-11,501	-19,039	-24,803	-17,222	-5,211
Net Cash From Continuing Financing Activities	5,771	-3,928	-5,512	-14,396	18,708	-11,501	-19,039	-24,803	-17,222	-5,211
Repayment of Debt	-4,018	-6,010	-25	-6,035	-4,501	-5,675	-9,390	-14,403	-4,101	-14,564
Repurchase of Common Equity	-7,768	-6,102	-1,410	-12,054	-1,053	-998	-934	-1,487	-2,010	-1,807
Payment of Dividends	-3,294	-3,717	-4,107	-5,580	-6,366	-7,716	-9,261	-10,043	-10,539	-11,025
Issuance of Debt	20,696	11,633	44	9,278	30,783	3,000	1,000	2,000	0.00	21,971
Other Financing Activities, net	155	268	-14	-5.00	-155	-112	-454	-870	-572	214
Effect of Exchange Rate Changes	-	-338	29	-39	7.00	-5.00	-97	-62	5.00	-65
Cash Interest Paid	536	986	1,099	1,215	1,794	2,619	2,712	2,546	2,469	2,811
Cash Income Taxes Paid	1,108	3,563	1,696	0.00	1,447	1,674	3,648	2,988	4,702	4,064

This table details how cash moves in and out of AbbVie's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	2,423	3,311	-2,631	-2,490	2,048	4,528	-473	5,253	-4,937	-5,873	-1,733
Net Cash From Operating Activities	5,005	7,602	7,428	4,193	6,319	7,574	4,753	4,040	2,271	5,447	7,048
Net Cash From Continuing Operating Activities	5,005	7,602	7,428	4,193	6,319	7,574	4,753	4,040	2,271	5,447	7,048
Net Income / (Loss) Continuing Operations	928	3,952	2,472	241	2,027	1,781	824	1,372	1,373	1,564	-23
Consolidated Net Income / (Loss)	928	3,952	2,472	241	2,027	1,781	824	1,372	1,373	1,564	-23
Depreciation Expense	203	181	196	179	190	196	187	183	184	191	206
Amortization Expense	1,849	2,024	1,961	1,948	2,070	2,039	1,889	1,891	1,947	1,888	1,896
Non-Cash Adjustments To Reconcile Net Income	2,180	781	355	1,031	294	1,786	1,105	76	689	-25	5,854
Changes in Operating Assets and Liabilities, net	-155	664	2,444	794	1,738	1,772	748	518	-1,922	1,829	-885
Net Cash From Investing Activities	130	1,286	-448	-499	-341	-369	-800	-9,588	-1,102	-8,256	-1,874
Net Cash From Continuing Investing Activities	130	1,286	-448	-499	-341	-369	-800	-9,588	-1,102	-8,256	-1,874
Purchase of Property, Plant & Equipment	-143	-177	-213	-175	-178	-219	-205	-193	-241	-249	-291
Purchase of Investments	-214	-117	-55	-372	-176	-165	-587	-196	-859	-223	-1,819
Sale and/or Maturity of Investments	42	1,410	70	22	14	5.00	14	6.00	3.00	507	39
Other Investing Activities, net	445	170	5.00	26	-1.00	10	-22	-6.00	-5.00	3.00	197
Net Cash From Financing Activities	-2,679	-5,518	-9,634	-6,192	-3,920	-2,661	-4,449	10,819	-6,097	-3,072	-6,861
Net Cash From Continuing Financing Activities	-2,679	-5,518	-9,634	-6,192	-3,920	-2,661	-4,449	10,819	-6,097	-3,072	-6,861
Repayment of Debt	3.00	-2,686	-6,862	-1,330	-1,003	28	-1,796	-5,183	-3,348	-371	-5,662
Repurchase of Common Equity	-9.00	-4.00	-4.00	-1,955	-10	-4.00	-41	-1,324	-9.00	-17	-457
Payment of Dividends	-2,507	-2,504	-2,506	-2,661	-2,625	-2,627	-2,626	-2,772	-2,750	-2,751	-2,752
Issuance of Debt	-	-	-	0.00	-	-	-	19,971	-	-	2,000
Other Financing Activities, net	-166	-324	-262	-246	-282	-58	14	127	10	67	10
Effect of Exchange Rate Changes	-33	-59	23	8.00	-10	-16	23	-18	-9.00	8.00	-46

This table presents AbbVie's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	53,050	66,099	70,786	59,352	89,115	150,565	146,529	138,805	134,711	135,161
Total Current Assets	16,314	16,187	21,223	16,945	49,519	24,173	27,928	28,463	33,002	25,582
Cash & Equivalents	8,399	5,100	9,303	7,289	39,924	8,449	9,746	9,201	12,814	5,524
Short-Term Investments	8.00	1,323	486	772	0.00	30	84	28	2.00	31
Accounts Receivable	4,730	4,758	5,088	5,384	5,428	8,822	9,977	11,254	11,155	10,919
Inventories, net	1,719	1,444	1,605	1,605	1,813	3,310	3,128	3,579	4,099	4,181
Prepaid Expenses	1,458	3,562	4,741	1,895	2,354	3,562	4,993	4,401	4,932	4,927
Plant, Property, & Equipment, net	2,565	2,604	2,803	2,883	2,962	5,248	5,110	4,935	4,989	5,134
Total Noncurrent Assets	34,171	47,308	46,760	39,524	36,634	121,144	113,491	105,407	96,720	104,445
Long-Term Investments	145	1,783	2,090	1,420	93	293	277	241	304	279
Goodwill	13,168	15,416	15,785	15,663	15,604	33,124	32,379	32,156	32,293	34,956
Intangible Assets	19,709	28,897	27,559	21,233	18,649	82,876	75,951	67,439	55,610	60,068
Other Noncurrent Operating Assets	1,149	1,212	1,326	1,208	2,288	4,851	4,884	5,571	8,513	9,142
Total Liabilities & Shareholders' Equity	53,050	66,099	70,786	59,352	89,115	150,565	146,529	138,805	134,711	135,161
Total Liabilities	49,105	61,463	65,689	67,798	97,287	137,468	131,093	121,518	124,314	131,797
Total Current Liabilities	10,894	9,781	16,641	17,239	15,585	28,661	35,194	29,538	37,841	38,749
Short-Term Debt	2,431	402	6,415	5,308	3,753	8,502	12,495	4,136	7,191	6,804
Accounts Payable	8,463	9,379	10,226	11,931	11,832	20,159	22,699	25,402	30,650	31,945
Total Noncurrent Liabilities	38,211	51,682	49,048	50,559	81,702	108,807	95,899	91,980	86,473	93,048
Long-Term Debt	32,935	44,792	46,558	49,492	62,975	77,554	64,189	59,135	52,194	60,340
Noncurrent Deferred & Payable Income Tax Liabilities	5,276	6,890	2,490	1,067	1,130	3,646	3,009	2,190	1,952	2,579
Other Noncurrent Operating Liabilities	-	-	-	-	17,597	27,607	28,701	30,655	32,327	30,129
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	3,945	4,636	5,097	-8,446	-8,172	13,097	15,436	17,287	10,397	3,364
Total Preferred & Common Equity	3,945	4,636	5,097	-8,446	-8,172	13,076	15,408	17,254	10,360	3,325
Total Common Equity	3,945	4,636	5,097	-8,446	-8,172	13,076	15,408	17,254	10,360	3,325
Common Stock	13,097	13,696	14,288	14,774	15,211	17,402	18,323	19,263	20,198	21,351
Retained Earnings	2,248	4,378	5,459	3,368	4,717	1,055	3,127	4,784	-1,000	-7,900
Treasury Stock	-8,839	-10,852	-11,923	-24,108	-24,504	-2,264	-3,143	-4,594	-6,533	-8,201
Accumulated Other Comprehensive Income / (Loss)	-2,561	-2,586	-2,727	-2,480	-3,596	-3,117	-2,899	-2,199	-2,305	-1,925
Noncontrolling Interest	-	-	-	-	0.00	21	28	33	37	39

This table presents AbbVie's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Total Assets	143,186	141,325	138,805	134,544	135,367	136,221	134,711	148,874	141,937	143,422	135,161
Total Current Assets	29,100	30,364	28,463	26,488	28,852	33,224	33,002	38,871	33,816	27,785	25,582
Cash & Equivalents	8,521	11,832	9,201	6,711	8,759	13,287	12,814	18,067	13,130	7,257	5,524
Short-Term Investments	1,440	47	28	11	7.00	3.00	2.00	2.00	27	28	31
Accounts Receivable	11,237	10,743	11,254	11,473	11,491	11,412	11,155	11,949	11,724	11,472	10,919
Inventories, net	3,396	3,172	3,579	3,833	4,055	3,981	4,099	4,245	4,218	4,450	4,181
Prepaid Expenses	4,506	4,570	4,401	4,460	4,540	4,541	4,932	4,608	4,717	4,578	4,927
Plant, Property, & Equipment, net	4,958	4,893	4,935	4,931	4,943	4,934	4,989	4,980	5,023	5,141	5,134
Total Noncurrent Assets	109,128	106,068	105,407	103,125	101,572	98,063	96,720	105,023	103,098	110,496	104,445
Long-Term Investments	244	235	241	257	288	275	304	305	272	267	279
Goodwill	32,028	31,726	32,156	32,220	32,224	32,091	32,293	33,426	33,386	35,295	34,956
Intangible Assets	71,823	68,725	67,439	64,848	62,862	58,603	55,610	62,225	60,243	66,646	60,068
Other Noncurrent Operating Assets	5,033	5,382	5,571	5,800	6,198	7,094	8,513	9,067	9,197	8,288	9,142
Total Liabilities & Shareholders' Equity	143,186	141,325	138,805	134,544	135,367	136,221	134,711	148,874	141,937	143,422	135,161
Total Liabilities	128,498	125,298	121,518	121,241	122,469	124,092	124,314	140,827	135,116	137,351	131,797
Total Current Liabilities	34,473	32,712	29,538	27,590	32,239	34,773	37,841	41,522	41,915	43,062	38,749
Short-Term Debt	11,930	9,207	4,136	2,801	5,203	5,115	7,191	10,196	12,586	12,570	6,804
Accounts Payable	22,543	23,505	25,402	24,789	27,036	29,658	30,650	31,326	29,329	30,492	31,945
Total Noncurrent Liabilities	94,025	92,586	91,980	93,651	90,230	89,319	86,473	99,305	93,201	94,289	93,048
Long-Term Debt	61,002	60,399	59,135	59,292	55,812	55,631	52,194	63,805	58,048	58,509	60,340
Noncurrent Deferred & Payable Income Tax Liabilities	2,255	1,972	2,190	2,110	2,124	2,044	1,952	2,722	2,726	2,749	2,579
Other Noncurrent Operating Liabilities	30,768	30,215	30,655	32,249	32,294	31,644	32,327	32,778	32,427	33,031	30,129
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	14,688	16,027	17,287	13,303	12,898	12,129	10,397	8,047	6,821	6,071	3,364
Total Preferred & Common Equity	14,653	15,994	17,254	13,274	12,866	12,094	10,360	8,007	6,778	6,032	3,325
Total Common Equity	14,653	15,994	17,254	13,274	12,866	12,094	10,360	8,007	6,778	6,032	3,325
Common Stock	18,924	19,074	19,263	19,637	19,857	20,039	20,198	20,674	20,897	21,178	21,351
Retained Earnings	3,516	4,953	4,784	2,393	1,789	933	-1,000	-2,384	-3,768	-4,964	-7,900
Treasury Stock	-4,591	-4,590	-4,594	-6,524	-6,528	-6,525	-6,533	-7,829	-7,838	-7,848	-8,201
Accumulated Other Comprehensive Income / (Loss)	-3,196	-3,443	-2,199	-2,232	-2,252	-2,353	-2,305	-2,454	-2,513	-2,334	-1,925
Noncontrolling Interest	35	33	33	29	32	35	37	40	43	39	39

This table displays calculated financial ratios and metrics derived from AbbVie's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	14.52%	12.16%	10.06%	16.08%	1.57%	37.69%	22.69%	3.30%	-6.44%	3.71%
EBITDA Growth	130.32%	22.91%	1.93%	-20.78%	47.45%	1.65%	96.67%	0.39%	-30.67%	-14.25%
EBIT Growth	165.62%	20.71%	-1.33%	-27.37%	56.68%	-42.85%	170.75%	0.96%	-48.88%	-25.94%
NOPAT Growth	128.42%	20.87%	-7.01%	6.51%	73.87%	27.27%	3.11%	-0.09%	-37.54%	5.95%
Net Income Growth	189.97%	15.73%	-10.82%	7.12%	38.60%	-41.36%	149.87%	2.56%	-58.86%	-12.05%
EPS Growth	184.55%	15.97%	-9.09%	10.91%	44.26%	-48.48%	137.13%	2.79%	-58.97%	-12.13%
Operating Cash Flow Growth	324.51%	-6.56%	41.46%	34.81%	-0.77%	32.00%	29.50%	9.51%	-8.44%	-17.66%
Free Cash Flow Firm Growth	-486.93%	70.65%	152.22%	718.79%	86.95%	-285.00%	143.10%	10.46%	-9.22%	-89.63%
Invested Capital Growth	157.74%	35.32%	10.97%	-20.17%	-49.72%	387.52%	-9.26%	-13.32%	-20.29%	14.14%
Revenue Q/Q Growth	4.33%	1.57%	3.46%	1.76%	1.21%	12.68%	1.86%	0.41%	-1.49%	1.44%
EBITDA Q/Q Growth	61.15%	2.37%	-7.27%	-29.71%	89.65%	-19.07%	30.93%	-4.85%	-10.41%	-18.43%
EBIT Q/Q Growth	70.49%	1.90%	-8.81%	-35.56%	128.29%	-43.76%	59.44%	-8.28%	-18.92%	-35.61%
NOPAT Q/Q Growth	52.33%	-0.86%	-16.48%	-23.71%	68.77%	44.38%	-8.22%	-0.83%	-18.97%	6.90%
Net Income Q/Q Growth	82.61%	-2.07%	-20.14%	-24.82%	142.15%	-37.41%	53.13%	-11.72%	-25.27%	-16.50%
EPS Q/Q Growth	84.12%	-2.16%	-19.71%	0.00%	0.00%	-42.49%	58.87%	-11.48%	-25.89%	-16.72%
Operating Cash Flow Q/Q Growth	27.73%	-5.65%	11.70%	6.40%	-0.87%	9.86%	0.98%	10.42%	-10.48%	13.90%
Free Cash Flow Firm Q/Q Growth	18.52%	-8.45%	-75.09%	102.47%	104.98%	-17.32%	-18.28%	10.42%	-7.97%	687.62%
Invested Capital Q/Q Growth	-2.25%	-1.12%	10.09%	-14.37%	-47.61%	-4.01%	0.29%	-3.31%	-4.46%	-7.07%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	80.31%	77.25%	75.04%	76.44%	77.64%	63.40%	68.96%	68.80%	60.98%	69.99%
EBITDA Margin	35.73%	39.15%	36.26%	24.75%	35.93%	26.52%	42.52%	41.32%	30.62%	25.32%
Operating Margin	32.97%	36.43%	33.83%	19.49%	39.03%	24.81%	31.89%	31.21%	23.49%	16.22%
EBIT Margin	32.07%	34.52%	30.94%	19.36%	29.87%	12.40%	27.36%	26.74%	14.61%	10.43%
Profit (Net Income) Margin	22.50%	23.22%	18.82%	17.36%	23.69%	10.09%	20.55%	20.40%	8.97%	7.61%
Tax Burden Percent	77.41%	75.51%	68.71%	109.43%	93.54%	136.02%	88.91%	87.89%	77.97%	115.34%
Interest Burden Percent	90.64%	89.09%	88.50%	81.96%	84.81%	59.85%	84.49%	86.83%	78.77%	63.24%
Effective Tax Rate	22.59%	24.49%	31.29%	-9.43%	6.46%	-36.02%	11.09%	12.11%	22.03%	-15.34%
Return on Invested Capital (ROIC)	27.33%	19.49%	14.94%	16.82%	43.83%	28.38%	18.49%	20.80%	15.57%	17.37%
ROIC Less NNEP Spread (ROIC-NNEP)	23.60%	16.04%	11.74%	13.81%	32.00%	7.54%	12.39%	14.03%	5.43%	5.75%
Return on Net Nonoperating Assets (RNNOA)	153.57%	119.26%	94.16%	-356.44%	-138.70%	159.31%	62.46%	51.59%	19.63%	44.92%
Return on Equity (ROE)	180.90%	138.75%	109.09%	-339.62%	-94.86%	187.70%	80.95%	72.40%	35.20%	62.29%
Cash Return on Invested Capital (CROIC)	-60.86%	-10.53%	4.53%	39.25%	110.01%	-103.54%	28.20%	35.07%	38.16%	4.16%
Operating Return on Assets (OROA)	18.20%	14.85%	12.76%	9.75%	13.38%	4.74%	10.35%	10.88%	5.80%	4.35%
Return on Assets (ROA)	12.77%	9.99%	7.76%	8.74%	10.62%	3.86%	7.77%	8.30%	3.56%	3.18%
Return on Common Equity (ROCE)	180.90%	138.75%	109.09%	-339.62%	-94.86%	186.90%	80.81%	72.26%	35.12%	61.95%
Return on Equity Simple (ROE_SIMPLE)	130.39%	128.41%	104.16%	-67.33%	-96.45%	35.35%	74.95%	68.65%	47.04%	128.90%
Net Operating Profit after Tax (NOPAT)	5,835	7,052	6,558	6,985	12,145	15,456	15,937	15,923	9,946	10,539
NOPAT Margin	25.52%	27.51%	23.24%	21.33%	36.51%	33.74%	28.36%	27.43%	18.31%	18.71%
Net Nonoperating Expense Percent (NNEP)	3.73%	3.45%	3.20%	3.00%	11.84%	20.84%	6.10%	6.78%	10.14%	11.62%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	19.77%	14.25%	14.95%
Cost of Revenue to Revenue	19.69%	22.75%	24.96%	23.56%	22.36%	36.60%	31.04%	31.20%	39.02%	30.01%
SG&A Expenses to Revenue	27.94%	22.94%	22.31%	22.59%	20.87%	24.67%	23.97%	26.29%	23.70%	31.08%
R&D to Revenue	19.40%	17.88%	18.90%	32.83%	20.42%	13.93%	12.32%	11.21%	14.13%	22.71%
Operating Expenses to Revenue	47.34%	40.82%	41.21%	56.95%	38.61%	38.59%	37.06%	37.60%	37.50%	53.77%
Earnings before Interest and Taxes (EBIT)	7,331	8,849	8,731	6,341	9,935	5,678	15,373	15,521	7,934	5,876
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	8,167	10,038	10,232	8,106	11,952	12,149	23,894	23,988	16,632	14,262
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	16.90	15.69	22.45	0.00	0.00	12.42	13.98	15.22	25.24	93.56
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.92	2.84	4.05	3.26	3.20	3.55	3.83	4.52	4.81	5.52
Price to Earnings (P/E)	12.96	12.22	21.55	18.77	13.51	35.18	18.66	22.18	53.77	72.72
Dividend Yield	4.95%	5.09%	3.57%	5.06%	5.94%	5.13%	4.27%	3.80%	4.00%	3.52%
Earnings Yield	7.72%	8.18%	4.64%	5.33%	7.40%	2.84%	5.36%	4.51%	1.86%	1.38%
Enterprise Value to Invested Capital (EV/IC)	3.04	2.64	3.37	4.12	7.19	2.65	3.44	4.45	5.43	5.76
Enterprise Value to Revenue (EV/Rev)	4.09	4.28	5.51	4.64	4.00	5.23	5.02	5.45	5.67	6.61
Enterprise Value to EBITDA (EV/EBITDA)	11.45	10.93	15.20	18.76	11.15	19.73	11.80	13.19	18.51	26.11
Enterprise Value to EBIT (EV/EBIT)	12.75	12.40	17.81	23.98	13.41	42.22	18.34	20.38	38.79	63.38
Enterprise Value to NOPAT (EV/NOPAT)	16.02	15.56	23.71	21.77	10.97	15.51	17.69	19.87	30.95	35.34
Enterprise Value to Operating Cash Flow (EV/OCF)	12.41	15.59	15.61	11.33	10.00	13.63	12.38	12.68	13.48	19.80
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	78.10	9.33	4.37	0.00	11.60	11.78	12.63	147.41
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	8.96	9.75	10.39	-6.49	-8.17	6.57	4.97	3.66	5.71	19.96
Long-Term Debt to Equity	8.35	9.66	9.13	-5.86	-7.71	5.92	4.16	3.42	5.02	17.94
Financial Leverage	6.51	7.44	8.02	-25.80	-4.33	21.12	5.04	3.68	3.61	7.82
Leverage Ratio	14.17	13.89	14.06	-38.86	-8.93	48.67	10.41	8.72	9.88	19.61
Compound Leverage Factor	12.84	12.37	12.45	-31.85	-7.58	29.12	8.80	7.57	7.78	12.40
Debt to Total Capital	89.96%	90.70%	91.22%	118.22%	113.96%	86.79%	83.24%	78.54%	85.10%	95.23%
Short-Term Debt to Total Capital	6.18%	0.81%	11.05%	11.45%	6.41%	8.57%	13.56%	5.13%	10.30%	9.65%
Long-Term Debt to Total Capital	83.78%	89.89%	80.18%	106.77%	107.55%	78.22%	69.68%	73.41%	74.80%	85.58%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.02%	0.03%	0.04%	0.05%	0.06%
Common Equity to Total Capital	10.04%	9.30%	8.78%	-18.22%	-13.96%	13.19%	16.73%	21.42%	14.85%	4.72%
Debt to EBITDA	4.33	4.50	5.18	6.76	5.58	7.08	3.21	2.64	3.57	4.71
Net Debt to EBITDA	3.28	3.68	4.02	5.59	2.23	6.36	2.79	2.24	2.78	4.30
Long-Term Debt to EBITDA	4.03	4.46	4.55	6.11	5.27	6.38	2.69	2.47	3.14	4.23
Debt to NOPAT	6.06	6.41	8.08	7.85	5.49	5.57	4.81	3.97	5.97	6.37
Net Debt to NOPAT	4.60	5.24	6.27	6.49	2.20	5.00	4.18	3.38	4.65	5.82
Long-Term Debt to NOPAT	5.64	6.35	7.10	7.09	5.19	5.02	4.03	3.71	5.25	5.73
Altman Z-Score	1.88	1.75	2.04	1.92	1.93	1.11	1.69	2.12	1.81	1.78
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.43%	0.17%	0.19%	0.25%	0.55%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.50	1.65	1.28	0.98	3.18	0.84	0.79	0.96	0.87	0.66
Quick Ratio	1.21	1.14	0.89	0.78	2.91	0.60	0.56	0.69	0.63	0.43
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-12,990	-3,813	1,991	16,303	30,479	-56,386	24,305	26,848	24,372	2,527
Operating Cash Flow to CapEx	1,416.35%	1,469.94%	1,882.80%	2,104.55%	2,413.77%	2,204.01%	2,894.16%	3,588.92%	2,939.38%	1,930.80%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.57	0.43	0.41	0.50	0.45	0.38	0.38	0.41	0.40	0.42
Accounts Receivable Turnover	5.40	5.40	5.73	6.26	6.15	6.43	5.98	5.47	4.85	5.10
Inventory Turnover	3.17	3.69	4.62	4.81	4.35	6.54	5.42	5.40	5.52	4.08
Fixed Asset Turnover	9.05	9.92	10.44	11.52	11.38	11.16	10.85	11.56	10.95	11.13
Accounts Payable Turnover	0.58	0.65	0.72	0.70	0.63	1.05	0.81	0.75	0.76	0.54
Days Sales Outstanding (DSO)	67.58	67.54	63.68	58.35	59.32	56.78	61.05	66.74	75.29	71.51
Days Inventory Outstanding (DIO)	115.30	98.98	79.02	75.90	83.85	55.77	67.35	67.58	66.12	89.39
Days Payable Outstanding (DPO)	625.25	558.33	508.08	523.92	582.97	348.29	448.33	484.70	482.68	675.79
Cash Conversion Cycle (CCC)	-442.36	-391.81	-365.38	-389.67	-439.81	-235.74	-319.93	-350.37	-341.27	-514.89
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	30,759	41,624	46,191	36,873	18,539	90,381	82,013	71,088	56,662	64,674
Invested Capital Turnover	1.07	0.71	0.64	0.79	1.20	0.84	0.65	0.76	0.85	0.93
Increase / (Decrease) in Invested Capital	18,825	10,865	4,567	-9,318	-18,334	71,842	-8,368	-10,925	-14,426	8,012
Enterprise Value (EV)	93,473	109,742	155,500	152,086	133,216	239,699	281,950	316,377	307,792	372,436
Market Capitalization	66,659	72,754	114,406	106,767	106,505	162,394	215,345	262,543	261,490	311,087
Book Value per Share	$2.41	$2.85	$3.19	($5.61)	($5.53)	$7.41	$8.72	$9.76	$5.87	$1.88
Tangible Book Value per Share	($17.70)	($24.42)	($23.96)	($30.14)	($28.69)	($58.30)	($52.56)	($46.56)	($43.92)	($51.89)
Total Capital	39,311	49,830	58,070	46,354	58,556	99,153	92,120	80,558	69,782	70,508
Total Debt	35,366	45,194	52,973	54,800	66,728	86,056	76,684	63,271	59,385	67,144
Total Long-Term Debt	32,935	44,792	46,558	49,492	62,975	77,554	64,189	59,135	52,194	60,340
Net Debt	26,814	36,988	41,094	45,319	26,711	77,284	66,577	53,801	46,265	61,310
Capital Expenditures (CapEx)	532	479	529	638	552	798	787	695	777	974
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-556	385	1,208	-3,047	-2,237	-4,465	-4,601	-6,168	-10,464	-11,918
Debt-free Net Working Capital (DFNWC)	7,851	6,808	10,997	5,014	37,687	4,014	5,229	3,061	2,352	-6,363
Net Working Capital (NWC)	5,420	6,406	4,582	-294	33,934	-4,488	-7,266	-1,075	-4,839	-13,167
Net Nonoperating Expense (NNE)	691	1,099	1,249	1,298	4,263	10,834	4,388	4,078	5,073	6,253
Net Nonoperating Obligations (NNO)	26,814	36,988	41,094	45,319	26,711	77,284	66,577	53,801	46,265	61,310
Total Depreciation and Amortization (D&A)	836	1,189	1,501	1,765	2,017	6,471	8,521	8,467	8,698	8,386
Debt-free, Cash-free Net Working Capital to Revenue	-2.43%	1.50%	4.28%	-9.30%	-6.72%	-9.75%	-8.19%	-10.62%	-19.26%	-21.16%
Debt-free Net Working Capital to Revenue	34.35%	26.55%	38.97%	15.31%	113.29%	8.76%	9.30%	5.27%	4.33%	-11.30%
Net Working Capital to Revenue	23.71%	24.99%	16.24%	-0.90%	102.01%	-9.80%	-12.93%	-1.85%	-8.91%	-23.37%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.15	$3.65	$3.31	$3.67	$5.30	$2.73	$6.48	$6.65	$2.73	$2.40
Adjusted Weighted Average Basic Shares Outstanding	1.63B	1.62B	1.60B	1.54B	1.48B	1.67B	1.77B	1.77B	1.77B	1.77B
Adjusted Diluted Earnings per Share	$3.13	$3.63	$3.30	$3.66	$5.28	$2.72	$6.45	$6.63	$2.72	$2.39
Adjusted Weighted Average Diluted Shares Outstanding	1.64B	1.63B	1.60B	1.55B	1.48B	1.67B	1.78B	1.78B	1.77B	1.77B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.61B	1.59B	1.59B	1.48B	1.48B	1.77B	1.77B	1.77B	1.77B	1.77B
Normalized Net Operating Profit after Tax (NOPAT)	5,835	7,052	6,558	4,468	12,145	7,954	15,937	15,923	9,946	6,396
Normalized NOPAT Margin	25.52%	27.51%	23.24%	13.64%	36.51%	17.37%	28.36%	27.43%	18.31%	11.35%
Pre Tax Income Margin	29.07%	30.75%	27.39%	15.87%	25.33%	7.42%	23.11%	23.21%	11.51%	6.60%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	64.04%	62.44%	77.36%	98.12%	80.77%	166.94%	80.19%	84.79%	216.27%	257.23%
Augmented Payout Ratio	215.05%	164.94%	103.92%	310.08%	94.13%	188.53%	88.28%	97.34%	257.52%	299.39%

This table displays calculated financial ratios and metrics derived from AbbVie's official financial filings.

Metric	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.47%	3.28%	1.58%	-9.70%	-4.92%	-5.97%	-5.42%	0.70%	4.31%	3.83%	5.60%
EBITDA Growth	-5.09%	10.97%	-17.93%	-59.37%	41.33%	-35.43%	-34.51%	40.12%	-10.16%	3.66%	-87.92%
EBIT Growth	-3.05%	14.60%	-28.93%	-83.01%	78.66%	-51.99%	-53.79%	137.67%	-13.45%	13.78%	-204.34%
NOPAT Growth	-11.98%	11.35%	-4.54%	-67.34%	35.60%	-49.69%	-52.65%	55.75%	-27.02%	38.22%	-148.02%
Net Income Growth	20.68%	24.28%	-38.89%	-94.64%	118.43%	-54.93%	-66.67%	469.29%	-32.26%	-12.18%	-102.79%
EPS Growth	21.43%	24.16%	-38.05%	-94.82%	123.53%	-54.75%	-67.86%	492.31%	-32.46%	-12.00%	-106.67%
Operating Cash Flow Growth	2.35%	-4.20%	46.36%	-14.57%	26.25%	-0.37%	-36.01%	-3.65%	-64.06%	-28.08%	48.29%
Free Cash Flow Firm Growth	-14.91%	-22.97%	17.75%	29.66%	45.54%	31.45%	7.00%	-53.62%	-78.89%	-145.51%	-154.55%
Invested Capital Growth	-9.84%	-10.10%	-13.32%	-16.52%	-16.22%	-19.33%	-20.29%	-6.93%	-1.28%	17.35%	14.14%
Revenue Q/Q Growth	7.72%	1.57%	2.09%	-19.15%	13.42%	0.45%	2.69%	-13.92%	17.48%	-0.01%	4.44%
EBITDA Q/Q Growth	-49.91%	88.53%	-21.18%	-45.41%	74.21%	-13.86%	-20.06%	16.80%	11.70%	-0.61%	-90.68%
EBIT Q/Q Growth	-68.64%	185.54%	-29.73%	-73.00%	229.82%	-23.27%	-32.37%	38.87%	20.11%	0.87%	-162.02%
NOPAT Q/Q Growth	-39.89%	59.95%	10.95%	-69.38%	149.57%	-40.65%	4.43%	0.70%	16.94%	12.40%	-136.28%
Net Income Q/Q Growth	-79.35%	325.86%	-37.45%	-90.25%	741.08%	-12.14%	-53.73%	66.50%	0.07%	13.91%	-101.47%
EPS Q/Q Growth	-79.68%	333.33%	-36.65%	-90.71%	776.92%	-12.28%	-55.00%	71.11%	0.00%	14.29%	-103.41%
Operating Cash Flow Q/Q Growth	1.98%	51.89%	-2.29%	-43.55%	50.70%	19.86%	-37.25%	-15.00%	-43.79%	139.85%	29.39%
Free Cash Flow Firm Q/Q Growth	-4.24%	12.29%	25.18%	-3.67%	7.48%	1.42%	1.90%	-58.25%	-51.07%	-318.61%	-22.15%
Invested Capital Q/Q Growth	-5.54%	-5.03%	-3.31%	-3.76%	-5.20%	-8.56%	-4.46%	12.38%	0.55%	8.70%	-7.07%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	69.56%	65.83%	70.82%	66.17%	69.42%	52.96%	56.18%	65.41%	64.47%	70.87%	78.18%
EBITDA Margin	25.83%	47.95%	37.02%	25.00%	38.40%	32.93%	25.63%	34.78%	33.07%	32.88%	2.93%
Operating Margin	22.59%	31.08%	36.39%	22.64%	32.55%	16.38%	22.34%	22.73%	27.64%	26.49%	-9.87%
EBIT Margin	11.76%	33.06%	22.76%	7.60%	22.10%	16.88%	11.12%	17.94%	18.34%	18.50%	-10.99%
Profit (Net Income) Margin	6.36%	26.68%	16.35%	1.97%	14.62%	12.79%	5.76%	11.15%	9.49%	10.82%	-0.15%
Tax Burden Percent	78.44%	89.82%	83.37%	50.74%	77.66%	91.19%	67.99%	78.18%	63.98%	75.05%	1.01%
Interest Burden Percent	68.98%	89.85%	86.17%	51.13%	85.18%	83.07%	76.23%	79.48%	80.92%	77.91%	136.77%
Effective Tax Rate	21.56%	10.18%	16.63%	49.26%	22.34%	8.81%	32.01%	21.82%	36.02%	24.95%	0.00%
Return on Invested Capital (ROIC)	12.45%	20.78%	23.01%	8.67%	19.91%	12.40%	12.92%	14.64%	15.10%	17.13%	-6.41%
ROIC Less NNEP Spread (ROIC-NNEP)	10.01%	20.49%	19.49%	6.74%	17.33%	11.83%	10.22%	13.16%	12.92%	14.76%	-4.52%
Return on Net Nonoperating Assets (RNNOA)	49.92%	87.01%	71.71%	27.49%	72.05%	43.97%	36.95%	68.28%	71.55%	89.80%	-35.31%
Return on Equity (ROE)	62.37%	107.80%	94.71%	36.16%	91.96%	56.37%	49.86%	82.92%	86.65%	106.93%	-41.72%
Cash Return on Invested Capital (CROIC)	29.50%	31.31%	35.07%	36.10%	37.98%	39.88%	38.16%	22.62%	15.71%	-0.67%	4.16%
Operating Return on Assets (OROA)	4.63%	13.17%	9.26%	3.10%	8.89%	6.71%	4.42%	6.89%	7.27%	7.35%	-4.59%
Return on Assets (ROA)	2.51%	10.63%	6.65%	0.81%	5.88%	5.08%	2.29%	4.28%	3.77%	4.30%	-0.06%
Return on Common Equity (ROCE)	62.23%	107.58%	94.54%	36.09%	91.74%	56.24%	49.74%	82.65%	86.32%	106.49%	-41.49%
Return on Equity Simple (ROE_SIMPLE)	86.30%	83.89%	0.00%	57.20%	67.56%	53.92%	0.00%	74.98%	78.93%	85.10%	0.00%
Net Operating Profit after Tax (NOPAT)	2,585	4,134	4,587	1,404	3,505	2,080	2,172	2,187	2,558	2,875	-1,043
NOPAT Margin	17.72%	27.91%	30.34%	11.49%	25.28%	14.94%	15.19%	17.77%	17.69%	19.88%	-6.91%
Net Nonoperating Expense Percent (NNEP)	2.44%	0.29%	3.51%	1.93%	2.58%	0.57%	2.69%	1.47%	2.17%	2.37%	-1.90%
Return On Investment Capital (ROIC_SIMPLE)	-	-	5.69%	-	-	-	3.11%	-	-	-	-1.48%
Cost of Revenue to Revenue	30.44%	34.18%	29.18%	33.83%	30.58%	47.04%	43.82%	34.59%	35.53%	29.13%	21.82%
SG&A Expenses to Revenue	37.11%	22.31%	22.60%	24.86%	25.59%	24.21%	20.37%	26.93%	23.35%	29.65%	43.24%
R&D to Revenue	11.03%	10.90%	11.84%	18.75%	12.50%	12.37%	13.47%	15.75%	13.47%	14.73%	44.86%
Operating Expenses to Revenue	46.97%	34.75%	34.43%	43.53%	36.87%	36.58%	33.84%	42.68%	36.82%	44.38%	88.05%
Earnings before Interest and Taxes (EBIT)	1,715	4,897	3,441	929	3,064	2,351	1,590	2,208	2,652	2,675	-1,659
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3,767	7,102	5,598	3,056	5,324	4,586	3,666	4,282	4,783	4,754	443
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	16.93	13.73	15.22	20.04	17.59	20.78	25.24	39.42	44.28	57.37	93.56
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	4.33	3.80	4.52	4.69	4.04	4.56	4.81	5.80	5.46	6.23	5.52
Price to Earnings (P/E)	19.63	16.38	22.18	35.08	26.06	38.58	53.77	52.67	56.21	67.56	72.72
Dividend Yield	3.86%	4.45%	3.80%	3.80%	4.51%	4.11%	4.00%	3.35%	3.57%	3.13%	3.52%
Earnings Yield	5.09%	6.11%	4.51%	2.85%	3.84%	2.59%	1.86%	1.90%	1.78%	1.48%	1.38%
Enterprise Value to Invested Capital (EV/IC)	4.02	3.77	4.45	4.70	4.29	5.03	5.43	5.83	5.58	5.89	5.76
Enterprise Value to Revenue (EV/Rev)	5.42	4.79	5.45	5.66	4.97	5.41	5.67	6.82	6.50	7.38	6.61
Enterprise Value to EBITDA (EV/EBITDA)	12.68	10.99	13.19	16.45	13.20	16.08	18.51	20.79	20.64	23.43	26.11
Enterprise Value to EBIT (EV/EBIT)	19.07	16.37	20.38	29.25	22.57	30.51	38.79	40.30	40.61	44.89	63.38
Enterprise Value to NOPAT (EV/NOPAT)	19.89	17.26	19.87	23.61	19.25	24.32	30.95	36.42	38.46	41.55	35.34
Enterprise Value to Operating Cash Flow (EV/OCF)	13.56	12.27	12.68	13.26	10.90	11.70	13.48	16.37	19.17	24.81	19.80
Enterprise Value to Free Cash Flow (EV/FCFF)	12.91	11.40	11.78	11.83	10.30	11.27	12.63	24.85	35.30	0.00	147.41
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	4.97	4.34	3.66	4.67	4.73	5.01	5.71	9.20	10.36	11.71	19.96
Long-Term Debt to Equity	4.15	3.77	3.42	4.46	4.33	4.59	5.02	7.93	8.51	9.64	17.94
Financial Leverage	4.98	4.25	3.68	4.08	4.16	3.72	3.61	5.19	5.54	6.08	7.82
Leverage Ratio	10.67	9.80	8.72	9.38	10.10	9.86	9.88	13.27	14.06	15.37	19.61
Compound Leverage Factor	7.36	8.81	7.51	4.80	8.60	8.19	7.53	10.55	11.38	11.97	26.82
Debt to Total Capital	83.24%	81.28%	78.54%	82.36%	82.55%	83.36%	85.10%	90.19%	91.19%	92.13%	95.23%
Short-Term Debt to Total Capital	13.62%	10.75%	5.13%	3.72%	7.04%	7.02%	10.30%	12.43%	16.25%	16.29%	9.65%
Long-Term Debt to Total Capital	69.62%	70.53%	73.41%	78.64%	75.51%	76.34%	74.80%	77.77%	74.94%	75.84%	85.58%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.04%	0.04%	0.04%	0.04%	0.04%	0.05%	0.05%	0.05%	0.06%	0.05%	0.06%
Common Equity to Total Capital	16.72%	18.68%	21.42%	17.61%	17.41%	16.60%	14.85%	9.76%	8.75%	7.82%	4.72%
Debt to EBITDA	2.98	2.76	2.64	3.18	2.89	3.27	3.57	4.14	4.08	4.07	4.71
Net Debt to EBITDA	2.56	2.28	2.24	2.82	2.46	2.54	2.78	3.12	3.30	3.63	4.30
Long-Term Debt to EBITDA	2.49	2.40	2.47	3.04	2.65	3.00	3.14	3.57	3.35	3.35	4.23
Debt to NOPAT	4.67	4.34	3.97	4.56	4.22	4.95	5.97	7.26	7.60	7.21	6.37
Net Debt to NOPAT	4.01	3.58	3.38	4.05	3.59	3.84	4.65	5.46	6.16	6.44	5.82
Long-Term Debt to NOPAT	3.90	3.76	3.71	4.36	3.86	4.53	5.25	6.26	6.25	5.94	5.73
Altman Z-Score	1.59	1.60	1.84	1.78	1.59	1.67	1.65	1.72	1.68	1.78	1.59
Noncontrolling Interest Sharing Ratio	0.22%	0.20%	0.19%	0.20%	0.24%	0.24%	0.25%	0.32%	0.38%	0.41%	0.55%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.84	0.93	0.96	0.96	0.89	0.96	0.87	0.94	0.81	0.65	0.66
Quick Ratio	0.61	0.69	0.69	0.66	0.63	0.71	0.63	0.72	0.59	0.44	0.43
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	11,036	12,392	15,512	14,943	16,061	16,289	16,598	6,930	3,391	-7,413	-9,055
Operating Cash Flow to CapEx	3,500.00%	4,294.92%	3,487.32%	2,396.00%	3,550.00%	3,458.45%	2,318.54%	2,093.26%	942.32%	2,187.55%	2,421.99%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.39	0.40	0.41	0.41	0.40	0.40	0.40	0.38	0.40	0.40	0.42
Accounts Receivable Turnover	5.42	5.78	5.47	5.11	4.93	4.98	4.85	4.65	4.74	4.85	5.10
Inventory Turnover	5.06	5.69	5.40	4.93	4.79	5.41	5.52	5.28	5.37	4.71	4.08
Fixed Asset Turnover	11.33	11.54	11.56	11.34	11.32	11.22	10.95	10.98	11.04	11.02	11.13
Accounts Payable Turnover	0.79	0.79	0.75	0.76	0.72	0.73	0.76	0.76	0.79	0.66	0.54
Days Sales Outstanding (DSO)	67.31	63.20	66.74	71.42	74.04	73.33	75.29	78.57	77.03	75.20	71.51
Days Inventory Outstanding (DIO)	72.12	64.13	67.58	73.97	76.18	67.50	66.12	69.16	67.97	77.42	89.39
Days Payable Outstanding (DPO)	460.75	464.27	484.70	478.83	506.87	501.67	482.68	480.46	463.07	552.32	675.79
Cash Conversion Cycle (CCC)	-321.32	-336.94	-350.37	-333.43	-356.66	-360.84	-341.27	-332.72	-318.07	-399.70	-514.89
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	77,415	73,519	71,088	68,417	64,859	59,310	56,662	63,674	64,026	69,598	64,674
Invested Capital Turnover	0.70	0.74	0.76	0.75	0.79	0.83	0.85	0.82	0.85	0.86	0.93
Increase / (Decrease) in Invested Capital	-8,451	-8,258	-10,925	-13,539	-12,556	-14,209	-14,426	-4,743	-833	10,288	8,012
Enterprise Value (EV)	310,864	277,087	316,377	321,218	278,344	298,520	307,792	371,297	357,373	409,620	372,436
Market Capitalization	248,102	219,562	262,543	266,075	226,351	251,304	261,490	315,630	300,125	346,054	311,087
Book Value per Share	$8.29	$9.05	$9.76	$7.50	$7.29	$6.85	$5.87	$4.53	$3.84	$3.42	$1.88
Tangible Book Value per Share	($50.48)	($47.77)	($46.56)	($47.36)	($46.60)	($44.53)	($43.92)	($49.54)	($49.18)	($54.30)	($51.89)
Total Capital	87,620	85,633	80,558	75,396	73,913	72,875	69,782	82,048	77,455	77,150	70,508
Total Debt	72,932	69,606	63,271	62,093	61,015	60,746	59,385	74,001	70,634	71,079	67,144
Total Long-Term Debt	61,002	60,399	59,135	59,292	55,812	55,631	52,194	63,805	58,048	58,509	60,340
Net Debt	62,727	57,492	53,801	55,114	51,961	47,181	46,265	55,627	57,205	63,527	61,310
Capital Expenditures (CapEx)	143	177	213	175	178	219	205	193	241	249	291
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-3,404	-5,020	-6,168	-5,023	-6,950	-9,724	-10,464	-10,524	-8,670	-9,992	-11,918
Debt-free Net Working Capital (DFNWC)	6,557	6,859	3,061	1,699	1,816	3,566	2,352	7,545	4,487	-2,707	-6,363
Net Working Capital (NWC)	-5,373	-2,348	-1,075	-1,102	-3,387	-1,549	-4,839	-2,651	-8,099	-15,277	-13,167
Net Nonoperating Expense (NNE)	1,657	182	2,115	1,163	1,478	299	1,348	815	1,185	1,311	-1,020
Net Nonoperating Obligations (NNO)	62,727	57,492	53,801	55,114	51,961	47,181	46,265	55,627	57,205	63,527	61,310
Total Depreciation and Amortization (D&A)	2,052	2,205	2,157	2,127	2,260	2,235	2,076	2,074	2,131	2,079	2,102
Debt-free, Cash-free Net Working Capital to Revenue	-5.94%	-8.68%	-10.62%	-8.85%	-12.41%	-17.64%	-19.26%	-19.34%	-15.76%	-17.99%	-21.16%
Debt-free Net Working Capital to Revenue	11.43%	11.86%	5.27%	2.99%	3.24%	6.47%	4.33%	13.87%	8.16%	-4.87%	-11.30%
Net Working Capital to Revenue	-9.37%	-4.06%	-1.85%	-1.94%	-6.05%	-2.81%	-8.91%	-4.87%	-14.73%	-27.51%	-23.37%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.52	$2.22	$1.39	$0.13	$1.14	$1.00	$0.46	$0.77	$0.77	$0.88	($0.02)
Adjusted Weighted Average Basic Shares Outstanding	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B
Adjusted Diluted Earnings per Share	$0.51	$2.21	$1.40	$0.13	$1.14	$1.00	$0.45	$0.77	$0.77	$0.88	($0.03)
Adjusted Weighted Average Diluted Shares Outstanding	1.78B	1.78B	1.78B	1.78B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.77B	1.77B	1.77B	1.76B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B	1.77B
Normalized Net Operating Profit after Tax (NOPAT)	2,585	4,134	4,587	1,404	3,505	2,080	2,172	2,187	2,558	2,875	-1,043
Normalized NOPAT Margin	17.72%	27.91%	30.34%	11.49%	25.28%	14.94%	15.19%	17.77%	17.69%	19.88%	-6.91%
Pre Tax Income Margin	8.11%	29.71%	19.61%	3.89%	18.82%	14.02%	8.47%	14.26%	14.84%	14.41%	-15.02%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	76.40%	73.42%	84.79%	134.04%	118.45%	159.78%	216.27%	177.38%	201.40%	212.33%	257.23%
Augmented Payout Ratio	89.18%	85.44%	97.34%	160.02%	141.15%	190.03%	257.52%	200.35%	227.16%	239.43%	299.39%

Frequently Asked Questions About AbbVie's Financials

When does AbbVie's fiscal year end?

According to the most recent income statement we have on file, AbbVie's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has AbbVie's net income changed over the last 9 years?

AbbVie's net income appears to be on an upward trend, with a most recent value of $4.29 billion in 2024, falling from $5.14 billion in 2015. The previous period was $4.87 billion in 2023.

What is AbbVie's operating income?

AbbVie's total operating income in 2024 was $9.14 billion, based on the following breakdown:

Total Gross Profit: $39.43 billion
Total Operating Expenses: $30.29 billion

How has AbbVie revenue changed over the last 9 years?

Over the last 9 years, AbbVie's total revenue changed from $22.86 billion in 2015 to $56.33 billion in 2024, a change of 146.4%.

How much debt does AbbVie have?

AbbVie's total liabilities were at $131.80 billion at the end of 2024, a 6.0% increase from 2023, and a 168.4% increase since 2015.

How much cash does AbbVie have?

In the past 9 years, AbbVie's cash and equivalents has ranged from $5.10 billion in 2016 to $39.92 billion in 2019, and is currently $5.52 billion as of their latest financial filing in 2024.

How has AbbVie's book value per share changed over the last 9 years?

Over the last 9 years, AbbVie's book value per share changed from 2.41 in 2015 to 1.88 in 2024, a change of -22.0%.

Related Companies

This page (NYSE:ABBV) was last updated on 4/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbbVie (ABBV) Financials

Frequently Asked Questions About AbbVie's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AbbVie (ABBV) Financials

Annual Income Statements for AbbVie

Quarterly Income Statements for AbbVie

Annual Cash Flow Statements for AbbVie

Quarterly Cash Flow Statements for AbbVie

Annual Balance Sheets for AbbVie

Quarterly Balance Sheets for AbbVie

Annual Metrics and Ratios for AbbVie

Quarterly Metrics and Ratios for AbbVie

Frequently Asked Questions About AbbVie's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools